Effect of bronchodilators and inhaled corticosteroids on dyspnea in chronic obstructive pulmonary disease

Dyspnea: Mechanisms, Measurement, and Management, Third Edition

Volumn , Issue , 2014, Pages 161-175

  O'Donnell, Denis E ^a   Webb, Katherine A ^b   Mahler, Donald A ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920719354     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (89)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease-Revised 2011. Available at www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Jan21.pdf. Accessed February 26, 2013.
2. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, Ford G, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J 2007; 14(Suppl B): 5B-32B.
3. Fletcher CM, Elmes PC, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 2: 257-266.
4. Mahler DA, Weinberg DH, Wells C, Feinstein AR. The measurements of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
5. O'Donnell DE, Webb KA. Exercise testing. In: Celli B (ed). Pharmacotherapy in Chronic Obstructive Pulmonary Disease, Chapter 3, Volume 182. Marcel Dekker, New York, 2004: pp.45-71.
6. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis 1993; 148: 1351-1357.
7. O'Donnell DE, Bertley JC, Chau LKL, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation. Pathophysiologic mechanisms. Am JRespir Crit Care Med 1997; 155: 109-115.
8. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in COPD. Am J Respir Crit Care Med 2001; 164: 770-777.
9. O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.
10. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in COPD. Eur Respir J 2004; 24: 86-94.
11. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, Kesten S, O'Donnell D. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168-1178.
12. O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K. Effect of fluticasone propionate/ salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130: 647-656.
13. Peters MM, Webb KA, O'Donnell DE. Combined physiological effects of bronchodilators and hyperoxia on dyspnea and exercise performance in normoxic COPD. Thorax 2006; 61: 559-567.
14. Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B, Caracta C. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011; 105: 580-587.
15. O'Donnell DE, Hamilton AL, Webb KA. Sensory-mechanical relationships during high-intensity, constantwork-rate exercise in COPD. J Appl Physiol 2006; 101: 1025-1035.
16. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56: 248-255.
17. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003; 21: 267-272.
18. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557-1565.
19. Puente-Maestu L, Villar F, de Miguel J, Stringer WW, Sanz P, Sanz ML, Garcia de Pedro J, Martinez-Abad Y. Clinical relevance of constant power exercise duration changes in COPD. Eur Respir J 2009; 34: 340-345.
20. Oga T, Nishimura K, Tsukino M, Hajiro T, Ikeda A, Izumi T. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests. Am J Respir Crit Care Med 2000; 161: 1897-1901.
21. Zhang X, Waterman LA, Ward J, Baird JC, Mahler DA. Advantages of endurance treadmill walking compared with cycling to assess bronchodilator therapy. Chest 2010; 137: 1354-1361.
22. Hsai D, Casaburi R, Pradhan A, Torres E, Porszasz J. Physiological responses to linear treadmill and cycle ergometer exercise in COPD. Eur Respir J 2009; 34: 605-615.
23. Mahler DA, Gifford AH, Waterman LA, Ward J, Machala S, Baird JC. Mechanism of greater oxygen desaturation during walking compared with cycling in patients with COPD. Chest 2011; 140: 351-358.
24. Murray JA, Waterman LA, Ward J, Baird JC, Mahler DA. Perceptual and physiologic responses during treadmill and cycle exercise in patients with COPD. Chest 2009; 135: 384-390.
25. Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW, Newhouse MT. Bronchodilators in chronic airflow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987; 135: 1069-1074.
26. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. A comparison of the effects of salbutamol and ipratropium on exercise endurance in patients with COPD. Chest 2003; 123: 1810-1816.
27. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am JRespir Crit Care Med 1996; 153: 967-975.
28. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol zinafoate in the treatment of COPD. Chest 1999; 115: 957-965.
29. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Use of a long-acting inhaled ß2-adrenergic agonist, salme-terol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087-1092.
30. Mahler DA, Wire P, Horstman D, Chang C-N, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-1091.
31. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834-843.
32. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.
33. Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, Malolepszy J, Ruffin R, Sybrecht GW. Formoterol in patients with chronic obstructive pulmonary disease: A randomized, controlled, 3-month trial. Eur Respir J 2002; 19: 936-943.
34. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ Jr, Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium and salmeterol. Chest 2002; 122: 47-55.
35. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B, on behalf of the INLIGHT-2 study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: A placebo-controlled comparison. Eur Respir J 2011; 37: 273-279.
36. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-1670.
37. Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: Results of two double-blind, placebo-controlled 12-week studies. COPD 2012; 9: 629-636.
38. Kinoshita M, Lee SH, Hang L, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y, for the Indacaterol Asian COPD study investigators. Efficacy and safety of indacaterol 140 and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12-week, placebo-controlled study. Respirology 2012; 17: 379-389.
39. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: Indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155-162.
40. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, et al. Efficacy of a new once-daily long-acting inhaled ß2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65: 473-479.
41. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B; on behalf of the INTENSITY study investigators. Blinded 12-week comparison of once-daily inda-caterol and tiotropium in COPD. Eur Respir J 2011; 38: 797-803.
42. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C, on behalf of an international study group. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-820.
43. Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG, Jenkins RJ, Winter JH, Dhillon DP. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996; 51: 689-693.
44. Man WD, Mustfa N, Nikoletou D, Kaul S, Hart N, Rafferty GF, Donaldson N, Polkey MI, Moxham J. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004; 59: 471-476.
45. Neder JA, Fuld JP, Overend T, Thirlwell J, Carter R, Stevenson R, Ward SA. Effects of formoterol on exercise tolerance in severely disabled patients with COPD. Respir Med 2007; 101: 2056-2064.
46. Beeh KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011; 8: 340-345.
47. Worth H, Forster K, Eriksson G, Nihlen U, Peterson S, Magnussen H. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med 2010; 104: 1450-1459.
48. O'Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, Kramer B, on behalf of the INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011; 105: 1030-1036.
49. Vincken W, van Noord JA, Greefhorst APM, Bantje TA, Kesten S, Korducki L, Cornelissen PJG, on behalf of the Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209-216.
50. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:542-549.
51. Ikeda A, Nishimura K, Koyama H, Tsukino M, Mishima M, Izumi T. Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 48-53.
52. Teramoto S, Fukuchi Y, Orimo H. Effects of inhaled anticholinergic drug on dyspnea and gas exchange during exercise in patients with chronic obstructive pulmonary disease. Chest 1993; 103: 1774-1782.
53. Ayers ML, Mejia R, Ward J, Lentine T, Mahler DA. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnea in COPD. Eur Respir J 2001; 17: 1132-1137.
54. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr. A long-term evaluation of once-daily inhaled tiotro-pium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
55. Verkindre C, Bart F, Aguilaniu B, Fortin F, Guerin J-C, Le Merre C, Iacono P, Huchon G. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006; 73: 420-427.
56. Mahler DA, Matthay RA, Snyder PE, Wells CK, Loke J. Sustained-release theophylline reduces dyspnea in non reversible obstructive airways disease. Am Rev Respir Dis 1985; 131: 22-25.
57. Voduc N, Alvarex GG, Amjadi K, Tessier C, Sabri E, Aaron SD. Effect of theophylline on exercise capacity in COPD patients treated with combination long-acting bronchodilator therapy: A pilot study. Int J COPD 2012; 7: 245-252.
58. Kirsten DK, Wegner RE, Jorres RA, Magnussen H. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 1993; 104: 1101-1107.
59. Murciano D, Auclair MH, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521-1525.
60. Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ 1988; 297: 1506-1510.
61. Tsukino M, Nishimura K, Ikeda A, Hajiro T, Koyoma H, Izumi T. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998; 53: 269-273.
62. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2009; 151: 517-527.
63. Renkema TE, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996; 109: 1156-1162.
64. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New Engl J Med 2000; 343: 1902-1909.
65. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C; for the TRISTAN study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomized controlled trial. Lancet 2003; 361: 449-456.
66. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
67. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J, on behalf of the International COPD Study Group. Multicentre randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-780.
68. Guenette JA, Raghavan N, Harris-McAllister V, Preston ME, Webb KA, O'Donnell DE. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD. Respir Med 2011; 105: 1836-1845.
69. Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase ß2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 12: L41-L46.
70. Grundemann D, Schechinger B, Rappold GA, Schomig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1998; 1: 349-351.
71. Kumar SD, Brieva JL, Danta I, Wanner A. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am J Respir Crit Care Med 2000; 161: 918-921.
72. Kelly L, Kolbe J, Mitzner W, Spannhake EW, Bromberger-Barnea B, Menkes H. Bronchial blood flow affects recovery from constriction in dog lung periphery. J Appl Physiol 1986; 60: 1954-1959.
73. Paredi P, Ward S, Cramer D, Barnes PJ, Kharitonov SA. Normal bronchial blood flow in COPD is unaffected by inhaled corticosteroids and correlates with exhaled nitric oxide. Chest 2007; 131: 1075-1081.
74. Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809-817.
75. Tashkin DP, Donohue JF, Mahler DA, Huang H, Goodwin E, Schaefer K, Hanrahan JP, Andrews WT. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009; 103: 516-524.
76. Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled study. Respir Med 2008; 102: 479-487.
77. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Zaagsma J, Mueller A, Cornellissen PJ. Combining tiotro-pium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med 2010; 104: 995-1004.
78. Terzano C, Petroianni A, Conti V, Ceccarelli D, Graziani E, Sanduzzi A, D'Avelli S. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med 2008; 102: 1701-1707.
79. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann Int Med 2007; 146: 545-555.
80. Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K. Efficacy and safety of nebulized for-moterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs 2009; 69: 1205-1216.
81. Berton DC, Reis M, Siqueira AC, Barroco AC, Takara LS, Bravo DM, Andreoni S, Neder JA. Effects of tiotro-pium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med 2010; 104: 1288-1296.
82. Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B, on behalf of the INTRUST-1 and INTRUST-2 study investigators. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: A randomised, double-blind comparison. Thorax 2012; 67: 781-788.
83. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotro-pium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-517.
84. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
85. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: Results of a 6-month randomized clinical trial. Drugs 2008; 68: 1975-2000.
86. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: Results from a 1-year randomized controlled clinical trial. Drugs 2009; 69: 549-565.
87. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of "triple" therapy with salmeterol/flutica-sone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63: 592-598.
88. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741-750.
89. Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW. Additive benefits of tiotropium in COPD patients treated with long-acting ß-agonists and corticosteroids. Respirology 2006; 11: 598-602.